Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/71831
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKriangkrai Chawansuntatien_US
dc.contributor.authorKritsadee Rattanathammetheeen_US
dc.contributor.authorJiraprapa Wipasaen_US
dc.date.accessioned2021-01-27T04:16:28Z-
dc.date.available2021-01-27T04:16:28Z-
dc.date.issued2021-01-01en_US
dc.identifier.issn15353699en_US
dc.identifier.issn15353702en_US
dc.identifier.other2-s2.0-85099352150en_US
dc.identifier.other10.1177/1535370220981579en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85099352150&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/71831-
dc.description.abstract© 2021 by the Society for Experimental Biology and Medicine. The association between the presence of anti-interferon-γ autoantibodies and the onset of immunodeficiency with intracellular infections has been clearly established. No standard regimen to control the production of these pathogenic autoantibodies, apart from antimicrobial therapy to eliminate infections, contributes to the medical burden of this syndrome, which sometimes has a fatal outcome. In this review, we summarize the findings on anti-interferon-γ autoantibodies to facilitate further research and to provide guidance for treatment strategies.en_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleMinireview: Insights into anti-interferon-γ autoantibodiesen_US
dc.typeJournalen_US
article.title.sourcetitleExperimental Biology and Medicineen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.